Dexamethasone implant in retinal vein occlusions
Sang Beom Han, Moosang Kim, Seung-Jun Lee
Department of Ophthalmology, School of Medicine, Kangwon National University, Chuncheon, South Korea
We read the article entitled “Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy” by Wallsh et al with great interest.1 The authors investigated the efficacy of the intravitreal dexamethasone (DEX) implant in patients with retinal vein occlusions (RVOs) who have failed multiple anti-vascular endothelial growth factor (anti-VEGF) injections. They concluded that DEX should be considered as a treatment option in patients with RVOs who have failed anti-VEGF therapy. We congratulate the authors for this well-organized study, and would like to contribute to their findings.
View the original paper by Wallsh and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]